“Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.”

AUTHORS: Tzoneva G*, Perez-Garcia A*, Carpenter Z*, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe J, Tallman M, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T‡, Rabadan R‡, Ferrando A.‡

* These authors have contributed equally to this work. ‡ These authors have contributed equally to this work.

Nature Medicine 2013 February 03. doi:10.1038/nm.3078.

Previous
Previous

“The integrated landscape of driver genomic alterations in glioblastoma.”

Next
Next

“The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.”